Lilly’s New Weight-Loss Pill Foundayo Gets Off to a Slow Start
Lilly’s new weight-loss pill started slow, far behind Novo’s, but it’s too early to tell which drug will win.
Already have an account? Sign in.
Lilly’s new weight-loss pill started slow, far behind Novo’s, but it’s too early to tell which drug will win.
California jury found Lilly breached good faith in the 2017 rezpeg deal and awarded Nektar $90 million plus interest. Lilly plans to appeal.
Reuters: Solidigm is weighing a US IPO as early as 2027 that could value the AI storage business at $150 billion and raise $15 billion.
Investors focused on Zscaler’s sales engine after Tackett’s CRO promotion. Analysts say the change continues the current go-to-market plan.